|
GB201000699D0
|
|
Intestinal treatment
|
|
GB0900096D0
|
|
Intestinal treatment
|
|
CA2708706A1
|
|
Cannabinoid receptor modulators
|
|
GB0821711D0
|
|
Dihydroindolone derivatives
|
|
GB0821710D0
|
|
Derivatives of dihydroindolone
|
|
GB0817067D0
|
|
Intestinal treatment
|
|
GB0814245D0
|
|
Medicinal use of receptor ligands
|
|
GB0813350D0
|
|
Cannabinoid receptor modulators
|
|
GB0812031D0
|
|
Thiazole derivatives
|
|
GB0811212D0
|
|
CB1 Receptor Modulators
|
|
ZA200803094B
|
|
Y4 selective receptor agonists for therapeutic interventions
|
|
ZA200803098B
|
|
Y2 selective receptor agonists for therapeutic interventions
|
|
MX2009006214A
|
|
Cb1 receptor modulators.
|
|
GB0724096D0
|
|
Cannabinoid receptor modulators
|
|
GB0717998D0
|
|
Canabinoid receptor modulators
|
|
GB0710682D0
|
|
Medicinal use of receptor ligands
|
|
GB0708226D0
|
|
Y-receptor agonists
|
|
GB0701992D0
|
|
Grehlin Receptor Modulators
|
|
GB0625196D0
|
|
Modulators of cannabinoid receptor
|
|
GB0625197D0
|
|
Cannabinoid receptor modulators
|
